Syndax Pharma (SNDX)

Trade SNDX now with
7/10/2019 7:13:27 AM Syndax Pharma Says FDA Clearance Of IND Application To Begin A Phase 1/2 Trial For SNDX-5613 For R/R Acute Leukemias
5/28/2019 11:19:44 AM Sirnaomics Appoints Allan Shaw As CFO
4/1/2019 10:36:11 AM Syndax Pharmaceuticals Presents Updated Phase 2 Data From ENCORE 601 Trial Of Entinostat In Combination With KEYTRUDA
3/27/2019 7:02:17 AM Syndax Reports $26.2 Mln Offering Of Common Stock And Warrants
3/7/2019 4:27:55 PM Syndax Pharma Q4 Loss/share $0.70 Vs. Loss $0.80 Year Ago
12/3/2018 10:08:27 AM Syndax Pharmaceuticals Announces Presentation Of Preclinical Data From Menin-MLL Program
11/5/2018 4:15:06 PM Syndax Pharmaceuticals Q3 Loss/share $0.68, Same As Last Year
5/30/2018 4:06:03 PM Syndax And Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
5/17/2018 7:13:14 AM Syndax Announces Updated Results From Phase 2 ENCORE 601 Trial Of Entinostat In Combination With KEYTRUDA
1/10/2018 7:04:23 AM Syndax Says Clinical Collaboration To Evaluate Entinostat In Combination With Anti-PD-L1 Cancer Immunotherapy
1/5/2018 1:22:41 PM B. Riley FBR Starts Syndax Pharma (SNDX) At Buy With $40.00 Price Target